(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.04%) $83.41
(0.16%) $2.48
(0.12%) $2 341.80
(0.46%) $29.75
(1.43%) $992.30
(0.06%) $0.931
(0.17%) $10.67
(0.04%) $0.791
(0.01%) $86.76
Live Chart Being Loaded With Signals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States...
Stats | |
---|---|
Today's Volume | 71 897 |
Average Volume | 33 242 |
Market Cap | 12.92M |
EPS | $0.520 ( Q1 | 2024-05-10 ) |
Next earnings date | ( $-0.0700 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.370 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0820 (1.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Tosca Melissa | Buy | 100 | Common Stock |
2024-06-14 | Daniels Eric Joseph | Buy | 1 431 | Common Stock |
2024-06-13 | Parsons Erin | Buy | 5 260 | Common Stock |
2024-06-13 | Strem Brian M. | Buy | 3 000 | Common Stock |
2023-09-29 | Tosca Melissa | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 93 transactions |
Buy: 1 943 431 | Sell: 3 424 922 |
Volume Correlation
Kiora Pharmaceuticals, Correlation
10 Most Positive Correlations | |
---|---|
CYN | 0.808 |
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kiora Pharmaceuticals, Correlation - Currency/Commodity
Kiora Pharmaceuticals, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-62 424.00 (0.00 %) |
EPS: | $-23.26 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-62 424.00 (0.00 %) |
EPS: | $-23.26 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-134 028 (0.00 %) |
EPS: | $-18.55 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-143.31 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Kiora Pharmaceuticals,
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators